Journal Watch · Proceedings of the National Academy of Sciences (PNAS) · 2026
Splicing suppression alters the <i>STING</i> transcription start site to attenuate antiviral innate immunity.
Given the evolutionary conservation of splicing mechanisms and STING-like pathways, this mechanism may represent a broadly applicable regulatory principle in immune defense across species.
TL;DR
Given the evolutionary conservation of splicing mechanisms and STING-like pathways, this mechanism may represent a broadly applicable regulatory principle in immune defense across species.
Key findings
- Such a shift diverts <i>STING</i> expression from a functional antiviral isoform to a nonantiviral variant that partially suppresses STING activity, thereby disabling the cGLR-STING pathway.
- Our findings uncover an unconventional viral immune evasion strategy and an unexpected link between splicing suppression and STING-mediated antiviral response.
- Given the evolutionary conservation of splicing mechanisms and STING-like pathways, this mechanism may represent a broadly applicable regulatory principle in immune defense across species.
What they did
Here, we show that an insect picorna-like virus CrPV (Cricket Paralysis virus) inhibits STING-mediated antiviral activity by altering the transcription start site of <i>STING</i>. Mechanistically, CrPV infection down-regulates several spliceosomal genes and disrupts pre-mRNA splicing. This splicing impairment is sufficient to stall RNA polymerase II in transcriptional initiation condensates, reduce global transcription efficiency, and reprogram the transcription start site of <i>STING</i>.
Full abstract (original)
Background: The cGAS (cyclic GMP-AMP synthase)-STING (Stimulator of interferon genes) pathway plays a central role in antiviral innate immunity in vertebrates. Recent studies have shown that invertebrates possess a related cGLR (cGAS-like receptor)-STING pathway. However, due to the lack of direct evidence demonstrating viral evasion of cGLR-STING-mediated immunity, the functional importance of cGLR-STING pathway in antiviral responses remains uncertain in invertebrates.
What they did: Here, we show that an insect picorna-like virus CrPV (Cricket Paralysis virus) inhibits STING-mediated antiviral activity by altering the transcription start site of <i>STING</i>. Mechanistically, CrPV infection down-regulates several spliceosomal genes and disrupts pre-mRNA splicing. This splicing impairment is sufficient to stall RNA polymerase II in transcriptional initiation condensates, reduce global transcription efficiency, and reprogram the transcription start site of <i>STING</i>.
Results & conclusions: Such a shift diverts <i>STING</i> expression from a functional antiviral isoform to a nonantiviral variant that partially suppresses STING activity, thereby disabling the cGLR-STING pathway. Our findings uncover an unconventional viral immune evasion strategy and an unexpected link between splicing suppression and STING-mediated antiviral response. Given the evolutionary conservation of splicing mechanisms and STING-like pathways, this mechanism may represent a broadly applicable regulatory principle in immune defense across species.
Abstract © the authors / Proceedings of the National Academy of Sciences (PNAS) (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1073/pnas.2613025123 · PubMed 42776761.
Why it matters for pharma & biotech
- Directly relevant to teams in mRNA / delivery technology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: mRNA / delivery technology
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Proceedings of the National Academy of Sciences (PNAS) study find?
Given the evolutionary conservation of splicing mechanisms and STING-like pathways, this mechanism may represent a broadly applicable regulatory principle in immune defense across species.
What type of study is this?
It is a research study, published in Proceedings of the National Academy of Sciences (PNAS) in 2026. Here, we show that an insect picorna-like virus CrPV (Cricket Paralysis virus) inhibits STING-mediated antiviral activity by altering the transcription start site of <i>STING</i>.
Where can I read the original paper?
The original is at the publisher via DOI 10.1073/pnas.2613025123. PubMed ID: 42776761. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/splicing-suppression-alters-the-lt-i-gt-sting-lt-i-gt-transcription-star-025123/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides